BIOMARIN PHARMACEUTICAL INC (BMRN) 102.33 -2.06 (-1.97%)
102.33 -2.06 (-1.97%)
US09061G1013 - Common Stock - After market: 102.33 0 (0%)
Fundamental Rating
Overall BMRN gets a fundamental rating of 6 out of 10. We evaluated BMRN against 636 industry peers in the Biotechnology industry. While BMRN has a great health rating, its profitability is only average at the moment. BMRN is valued quite expensive, but it does show an excellent growth.
Profitability
Profitability Rating
BMRN has a Return On Assets of 1.34%. This is amongst the best returns in the industry. The industry average is -44.51%. BMRN outperforms 92% of its industry peers.
The Piotroski-F score of BMRN is 8.00. This is a very strong score and indicates great health and profitability for BMRN.
BMRN's Return On Equity of 1.84% is worse than the rest of the industry. The industry average Return On Equity is 22.42%. 92% of the industry peers have a better Return On Equity.
BMRN has a Profit Margin of 4.18%. This is below the industry average of 33.67%. 88% of the industry peers outperform BMRN.
VS Industry
ROA (1.34%) VS Industry: 92% outperformed.
-3,944.82
115.38
ROE (1.84%) VS Industry: 8% outperformed.
0.21
217.75
Profit Margin (4.18%) VS Industry: 12% outperformed.
0.84
1,971.30
Valuation
Valuation Rating
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a price book ratio of 4.16, BMRN is valued correctly.
The Price/Earnings Ratio is negative for BMRN. In the last year negative earnings were reported.
The Forward Price/Earnings Ratio of 48.78 indicates a quite expensive current valuation of BMRN.
Compared to an average industry price book ratio of 1.63, BMRN is valued more expensive than its industry peers. 82% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of BMRN to the average industry ratio of 12.10, BMRN is valued more expensive than its industry peers. 98% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Book (4.16) VS Industry: 18% outperformed.
134.19
0.09
Enterprise Value/ EBITDA (180.5) VS Industry: 2% outperformed.
3,131.28
0.70
Growth
Growth Rating
The Earnings Per Share is expected to grow by 122.60% on average over the next 5 years. This is a very strong growth
Measured over the past 5 years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.57% on average per year.
Based on estimates for the next 5 years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 16.58% on average per year.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
BMRN shows a small growth in Revenue. In the last year, the Revenue has grown by 8.64%.
BMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.50%.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -137.5% | 315.32% | 179.78% | 132.32% | 122.6% |
| Revenue | 10.57% | 7.38% | 8.64% | 13.84% | 18.25% | 19.9% | 16.58% |
Health
Health Rating
BMRN has a Current Ratio of 5.15. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Quick Ratio of 3.54. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has an Altman-Z score of 7.42. This indicates that BMRN is financially healthy and little risk of bankruptcy at the moment.
The Altman-Z score of BMRN is much better than the industry average of -0.65. BMRN has a better rating than 83% of its industry peers.
The Piotroski-F score of BMRN is 8.00. This is a very strong score and indicates great health and profitability for BMRN.
BMRN has a Current Ratio comparable to the industry average, which is at 6.12.
When comparing the Quick Ratio of BMRN to the average industry Current Ratio of 6.04, BMRN is less able to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.00, BMRN is requires more financing than its industry peers. 83% of its industry peers have a better Debt to Equity Ratio.
VS Industry
Debt/Equity (0.24) VS Industry: 17% outperformed.
15.37
0.00
Quick Ratio (3.54) VS Industry: 31% outperformed.
0.02
84.53
Current Ratio (5.15) VS Industry: 42% outperformed.
0.02
85.09
Altman-Z (7.42) VS Industry: 83% outperformed.
-1,822.17
440.11
Dividend
Dividend Rating
BMRN does not give a dividend.
BIOMARIN PHARMACEUTICAL INC102.33
NASDAQ:BMRN (12/9/2022, 7:00:01 PM)-2.06 (-1.97%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 10-26 2022-10-26/amc | Earnings (Next) | 02-21 2023-02-21 |
| Ins Owners | 0.55% | Inst Owners | 97.72% |
| Market Cap | 19.02B | Analysts | 84.29 |
| PE | N/A | Fwd PE | 48.78 |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 9.47 | P/B | 4.16 |
| EV/EBITDA | 180.5 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -137.5% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 80% |
| EPS Next Y | 315.32% | EPS Next 2Y | 179.78% |
| EPS Next 3Y | 132.32% | EPS Next 5Y | 122.6% |
| Revenue growth 1Y | 8.64% | Revenue growth 3Y | 7.38% |
| Revenue growth 5Y | 10.57% | Revenue growth Q2Q | 23.63% |
| Revenue Next Year | 13.84% | Revenue Next 2Y | 18.25% |
| Revenue Next 3Y | 19.9% | Revenue Next 5Y | 16.58% |
| Current Ratio | 5.15 | Quick Ratio | 3.54 |
| Altman-Z | 7.42 | F-Score | 8 |
| Debt/Equity | 0.24 | WACC | 8.73% |
| ROIC/WACC | 0 | ||
| ROA | 1.34% | ROE | 1.84% |
| ROICexgc | 0% | ROIC | 0% |
| PM | 4.18% | OM | 0.01% |
| Asset Turnover | 0.32 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA